TORONTO– Eli Lilly Canada Inc. announced today that Health Canada authorized Ebglyss ™ (lebrikizumab), a targeted IL-13 inhibitor, for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40kg, whose disease is not well controlled despite treatment with topical prescription therapies or when those therapies are not advisable.1
“As a physician, I recognize the heterogeneity of atopic dermatitis and the ongoing struggle to achieve long-term control,” said Dr. Melinda Gooderham, Dermatologist and Medical Director at SKiN Centre for Dermatology. “The approval of [Ebglyss] lebrikizumab provides patients with much-needed treatment diversity. Addressing the profound impact of severe itch, impact on sleep, and overall well-being underscores the urgency for innovative dermatological therapies and expanding treatment options.”
“Atopic dermatitis can negatively impact quality of life for the sufferer and their whole family,” said Amanda Cresswell-Melville, Executive Director of the Eczema Society of Canada. “Beyond the uncomfortable physical symptoms, the condition can also impact many facets of life including sleep, self-esteem, and mental health.”
The authorization was based on results from the ADvocate 1, ADvocate 2, and ADhere studies, which included over 1,000 adults and adolescents (aged 12 to less than 18 years who weighed at least 40 kg) with moderate-to-severe atopic dermatitis who were unable to control their symptoms with topical medicines or other systemic treatments, and who were candidates for systemic therapies.